Phase 1 Clinical Trial
Official title:
An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
The study is a monocentric, open label, phase 1 study to evaluate the pharmacokinetics, and in particular the dose proportionality of setanaxib and its metabolites after a single oral dose (400 mg, 800 mg, 1200 mg, and 1600 mg) (Part 1) and after multiple oral doses (Part 2).
The study is a monocentric, open label, phase 1 study to evaluate the pharmacokinetics, and in particular the dose proportionality of setanaxib and its metabolites after a single oral dose (400 mg, 800 mg, 1200 mg, and 1600 mg) (Part 1) and after multiple oral doses (Part 2). The study will include 2 parts conducted in separate cohorts of subjects. - Part 1 of the study will be an open label, single dose study evaluating the pharmacokinetics, and in particular the dose proportionality of setanaxib formulated as tablets, in 4 separate cohorts of 6 to 8 healthy adult subjects - Part 2 of the study will assess the pharmacokinetics of setanaxib tablets, expand the evaluation of potential drug-drug interactions, and assess the safety of setanaxib tablets at doses up to 1600mg/day for 14 days in separate 2 cohorts. The evaluation of drug-drug interactions will be carried out only at the top dose. Accordingly, a larger cohort (i.e. 16 subjects) will be included in Cohort 7. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02010944 -
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
|
Phase 1 | |
Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
Completed |
NCT05068947 -
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03273192 -
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects
|
Phase 1 | |
Completed |
NCT03883620 -
Safety Study of Dengushield in Healthy Adults
|
Phase 1 | |
Completed |
NCT01091532 -
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
|
Phase 1 | |
Completed |
NCT02634489 -
EC905 Pharmacokinetic Profile Study
|
Phase 1 | |
Completed |
NCT03647670 -
A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03488719 -
A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate
|
Phase 1 | |
Completed |
NCT03983876 -
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)
|
Phase 1 | |
Completed |
NCT03273088 -
Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03740217 -
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
|
Phase 1 | |
Recruiting |
NCT06214858 -
The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04014257 -
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
|
Phase 1 |